We are live on ! Find out more
NMRA icon

Neumora Therapeutics

98 hedge funds and large institutions have $41.1M invested in Neumora Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more call options, than puts

Call options by funds: $143K | Put options by funds: $54K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 28

5.63% less ownership

Funds ownership: 40.27%34.64% (-5.6%)

15% less funds holding

Funds holding: 11598 (-17)

37% less capital invested

Capital invested by funds: $65.2M → $41.1M (-$24.1M)

40% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 40

Holders
98
Holders Change
-17
Holders Change %
-14.78%
% of All Funds
1.29%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
24
Increased
28
Reduced
28
Closed
40
Calls
$143K
Puts
$54K
Net Calls
+$89K
Net Calls Change
-$63K

NMRA Hedge Fund Activity: Q2 2025 in Review

98 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2025, worth a combined $41.1M — down 37% from $65.2M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of NMRA and 24 opened new positions — a net loss of 16 holders — while 28 trimmed existing stakes and 28 added.

The largest buyer was Two Sigma Advisers, adding an estimated $798K. The largest seller was BlackRock, cutting an estimated $2.63M.

  • 98 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2025, down from 115 in Q1 2025.
  • Funds reported $41.1M of Neumora Therapeutics stock for Q2 2025, down 37% quarter-over-quarter.
  • 24 funds opened new Neumora Therapeutics positions in Q2 2025 and 40 closed out, a net change of -16 holders.
  • The largest Neumora Therapeutics buyer in Q2 2025 was Two Sigma Advisers, an estimated $798K added.
  • The largest Neumora Therapeutics seller in Q2 2025 was BlackRock, an estimated $2.63M sold.

Based on aggregated 13F filings for Q2 2025.